341 related articles for article (PubMed ID: 23721189)
1. Increase of interferon-γ inducible CXCL9 and CXCL11 serum levels in patients with active Graves' disease and modulation by methimazole therapy.
Antonelli A; Ferrari SM; Corrado A; Ferrannini E; Fallahi P
Thyroid; 2013 Nov; 23(11):1461-9. PubMed ID: 23721189
[TBL] [Abstract][Full Text] [Related]
2. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
Antonelli A; Rotondi M; Fallahi P; Romagnani P; Ferrari SM; Barani L; Ferrannini E; Serio M
Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy.
Antonelli A; Fallahi P; Rotondi M; Ferrari SM; Serio M; Miccoli P
Br J Surg; 2006 Oct; 93(10):1226-31. PubMed ID: 16838393
[TBL] [Abstract][Full Text] [Related]
4. Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis.
Antonelli A; Ferrari SM; Frascerra S; Di Domenicantonio A; Nicolini A; Ferrari P; Ferrannini E; Fallahi P
J Clin Endocrinol Metab; 2011 Jun; 96(6):1859-63. PubMed ID: 21470996
[TBL] [Abstract][Full Text] [Related]
5. Elevated serum IL-16 and RANTES levels in patients with autoimmune thyroid diseases and modulation by methimazole therapy.
Gu X; Zheng L; Chen X; Ruan L; Zhang H; Ge S; Zhu H; Lin X; Shen F
Horm Metab Res; 2012 Jun; 44(6):482-7. PubMed ID: 22473756
[TBL] [Abstract][Full Text] [Related]
6. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E
Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
[TBL] [Abstract][Full Text] [Related]
7. CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves' and normal thyrocytes.
Antonelli A; Ferrari SM; Frascerra S; Pupilli C; Mancusi C; Metelli MR; Orlando C; Ferrannini E; Fallahi P
J Clin Endocrinol Metab; 2010 Dec; 95(12):E413-20. PubMed ID: 20810571
[TBL] [Abstract][Full Text] [Related]
8. Influence of methimazole and radioactive iodine treatment in the serum levels of the chemokine CXCL10 in hyperthyroid patients with Graves' disease.
Leite AC; Pedro AB; Romaldini JH
Horm Metab Res; 2011 Mar; 43(3):194-9. PubMed ID: 21283953
[TBL] [Abstract][Full Text] [Related]
9. Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process.
Antonelli A; Fallahi P; Rotondi M; Ferrari SM; Romagnani P; Grosso M; Ferrannini E; Serio M
Eur J Endocrinol; 2006 May; 154(5):651-8. PubMed ID: 16645011
[TBL] [Abstract][Full Text] [Related]
10. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists.
Antonelli A; Ferrari SM; Fallahi P; Frascerra S; Santini E; Franceschini SS; Ferrannini E
J Clin Endocrinol Metab; 2009 May; 94(5):1803-9. PubMed ID: 19276231
[TBL] [Abstract][Full Text] [Related]
11. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.
Roti E; Gardini E; Minelli R; Bianconi L; Salvi M; Gavaruzzi G; Braverman LE
J Clin Endocrinol Metab; 1993 Apr; 76(4):928-32. PubMed ID: 7682562
[TBL] [Abstract][Full Text] [Related]
12. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment.
Amato G; Mazziotti G; Sorvillo F; Piscopo M; Lalli E; Biondi B; Iorio S; Molinari A; Giustina A; Carella C
Bone; 2004 Sep; 35(3):785-91. PubMed ID: 15336617
[TBL] [Abstract][Full Text] [Related]
13. [Analysis of costimulatory molecules (CD28-CTLA-4/B7) expression on chosen mononuclear cells in adolescents with Graves' disease during methimazole therapy].
Bossowski A; Stasiak-Barmuta A; Urban M; Rinderle C
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2004; 10(2):93-101. PubMed ID: 15504312
[TBL] [Abstract][Full Text] [Related]
14. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease.
Yamada T; Sato A; Komiya I; Nishimori T; Ito Y; Terao A; Eto S; Tanaka Y
J Clin Endocrinol Metab; 2000 Aug; 85(8):2775-8. PubMed ID: 10946880
[TBL] [Abstract][Full Text] [Related]
15. Significance of thyroid blood flow as a predictor of methimazole sensitivity in untreated hyperthyroid patients with Graves' disease.
Nagasaki T; Inaba M; Kumeda Y; Fujiwara-Ueda M; Hiura Y; Nishizawa Y
Biomed Pharmacother; 2007 Sep; 61(8):472-6. PubMed ID: 17420111
[TBL] [Abstract][Full Text] [Related]
16. The Th1 chemokine MIG in Graves' Disease: a narrative review of the literature.
Giusti C
Clin Ter; 2019; 170(4):e285-e290. PubMed ID: 31304517
[TBL] [Abstract][Full Text] [Related]
17. A patient-specific treatment model for Graves' hyperthyroidism.
Pandiyan B; Merrill SJ; Di Bari F; Antonelli A; Benvenga S
Theor Biol Med Model; 2018 Jan; 15(1):1. PubMed ID: 29310665
[TBL] [Abstract][Full Text] [Related]
18. High circulating chemokines (C-X-C motif) ligand 9, and (C-X-C motif) ligand 11, in hepatitis C-associated cryoglobulinemia.
Antonelli A; Fallahi P; Ferrari SM; Frascerra S; Mancusi C; Colaci M; Manfredi A; Sansonno D; Zignego AL; Ferri C
Int J Immunopathol Pharmacol; 2013; 26(1):49-57. PubMed ID: 23527708
[TBL] [Abstract][Full Text] [Related]
19. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter.
Antonelli A; Rotondi M; Fallahi P; Grosso M; Boni G; Ferrari SM; Romagnani P; Serio M; Mariani G; Ferrannini E
J Clin Endocrinol Metab; 2007 Apr; 92(4):1485-90. PubMed ID: 17244787
[TBL] [Abstract][Full Text] [Related]
20. The iodine perchlorate discharge test before and after one year of methimazole treatment of hyperthyroid Graves' disease.
Roti E; Minelli R; Gardini E; Bianconi L; Salvi M; Gavaruzzi G; Ugolotti G; Braverman LE
J Clin Endocrinol Metab; 1994 Mar; 78(3):795-9. PubMed ID: 8126159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]